GET DAILY SIGNALSElectromed (ELMD) Earnings Preview: Fiscal 2027 First Quarter Results
Key Takeaways
- Electromed, Inc. (NYSE American: ELMD) is scheduled to report its fiscal 2027 first quarter results — for the period ended September 30, 2026 — on November 10, 2026, after the market close.
- Wall Street consensus points to earnings per share (EPS) of about $0.26, compared with $0.25 in the same quarter a year earlier.
- Analysts estimate revenue of roughly $18.85 million, implying year-over-year growth of about 11.6%.
- Electromed enters the quarter on a 15-quarter streak of year-over-year revenue and profit growth, with management guiding for double-digit top-line growth in fiscal 2027.
- Investors will be watching home care demand, sales representative productivity, and gross margin durability in the low-70% range or better.
- For more context, explore Major News, Today's Price Move, Price Targets, and Forecast pages for the ticker.
- You can also discover actionable ideas by exploring Trending AI Robots.
Earnings Context and Why It Matters
Electromed is a medical device company best known for its SmartVest Airway Clearance System, which delivers high-frequency chest wall oscillation (HFCWO) therapy to patients with compromised pulmonary function, including those with bronchiectasis. The company operates on a fiscal year ending June 30, so this report covers the first quarter of fiscal 2027. Because Electromed generates nearly all of its revenue domestically and relies on a direct-to-patient sales model, quarterly results offer a timely read on referral volumes, reimbursement dynamics, and payer coverage. After a record fiscal 2026 — revenue of $73.8 million, up 15.3%, and diluted EPS of $1.30 — this print will signal whether that momentum carried into the new fiscal year and whether management's expansion plans are translating into sustained profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Consensus expectations for the fiscal 2027 first quarter call for EPS of approximately $0.26, a modest step up from $0.25 reported in the prior-year period. Analysts project revenue near $18.85 million, an increase of roughly 11.6% from a year earlier. For context, Electromed closed fiscal 2026 with fourth-quarter revenue of $19.4 million (up 11.6% year over year) and record quarterly EPS of $0.39. Management has guided for double-digit top-line growth and continued operating leverage in fiscal 2027, while targeting home care revenue per sales representative of $1,050,000 to $1,150,000 and planning to expand to about 67 territories. Key metrics investors will watch include gross margin (management expects mid-70% levels or better), direct home care revenue growth, and the pace of sales team expansion.
Market Reaction and Investor Sentiment
Sentiment heading into the print is broadly constructive, reflecting Electromed's consistent record of beating expectations and its streak of consecutive quarterly revenue and profit growth. However, the stock has shown meaningful post-earnings volatility in recent quarters, with moves in both directions following results. Key risk factors for this report include potential softness in the hospital channel — which declined 29% year over year in the fourth quarter of fiscal 2026 — as well as the leadership transition underway, given the CEO's planned retirement in April 2027. Investors will be weighing the durability of home care demand and sales representative productivity against rising selling, general, and administrative (SG&A) expenses tied to hiring. From what I see, this streak of growth makes the upcoming report particularly noteworthy.
Forward Outlook and Key Factors to Monitor
Beyond the headline numbers, investors should monitor several forward-looking signals. First, watch the trajectory of the direct home care business, which accounted for $66.6 million of fiscal 2026 revenue and remains the primary growth engine. Management's plan to expand from 64 direct sales representatives toward roughly 67 territories will be an important indicator of how quickly the company can scale while preserving productivity.
Second, keep an eye on margin trends. Electromed has committed to maintaining mid-70% or better gross margins, but SG&A spending rose 8.7% in fiscal 2026 as the company hired to support higher referral volumes. Any commentary on expense discipline and operating leverage will matter for profitability.
Finally, watch for updates on reimbursement and payer coverage. Electromed ended fiscal 2026 with contracts covering 87% of U.S. covered lives, and its Smart Order ePrescribe platform processed more than 45% of orders. Progress on electronic ordering ahead of anticipated standards from the Centers for Medicare & Medicaid Services (CMS), along with the CEO succession plan, are key catalysts that could shape the narrative through the remainder of fiscal 2027. I’m watching this closely for signs of continued execution.
Using AI Tools in My Research Process
I often rely on Tickeron’s AI Screener when preparing for earnings reports like this one. It allows me to quickly filter healthcare stocks by fundamentals, technical patterns, and performance metrics, helping surface comparable names and confirm trends without spending hours on manual analysis. This kind of tool has become a practical part of how I evaluate opportunities in the medical device space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ELMD's Indicator enters downward trend
The Aroon Indicator for ELMD entered a downward trend on November 04, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 172 similar instances where the Aroon Indicator formed such a pattern. In 120 of the 172 cases the stock moved lower. This puts the odds of a downward move at 70%.
Technical Analysis (Indicators)
Bearish Trend Analysis
ELMD moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ELMD moved below the 200-day moving average on October 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ELMD's RSI Indicator exited the oversold zone, 14 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 50%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 72 cases where ELMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ELMD as a result. In 88 of 118 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
Following a +3.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELMD advanced for three days, in 184 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
ELMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 42 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 52 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. ELMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.211) is normal, around the industry mean (4.142). P/E Ratio (19.832) is within average values for comparable stocks, (3.291). ELMD's Projected Growth (PEG Ratio) (103.010) is very high in comparison to the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.080) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of airway clearance products
Industry MedicalNursingServices
Advertisement